GlaxoSmithKline Offer To Acquire HGS Represents Full, Fair Value
May 17 2012 - 1:54PM
Dow Jones News
GlaxoSmithKline PLC (GSK.LN), a British pharmaceutical company,
said Thursday it believes its tender offer for Human Genome
Sciences(HGSI) represents full and fair value and is in the best
interests of both companies' shareholders, adding that it will
continue to proceed with its tender offer.
MAIN FACTS:
-The offer represents a premium of 81 percent to HGS's closing
share price of $7.17 on April 18.
-Tender offer to acquire all of Human Genome Sciences
outstanding shares for $13.00 per share in cash.
-The offer is not conditioned on due diligence or financing.
-The tender offer will close on June 7.
-GSK's offer incorporates the value of Benlysta, darapladib,
albiglutide and HGS's pipeline and financial assets.
-It also reflects expected cost synergies of at least $200
million.
-Shares at 1723 GMT down 1%, at 1409 pence, valuing the company
at GBP71 billion.
-By Mark Shapland, Dow Jones Newswires; +44 207 8429358;
mark.shapland@dowjones.com
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Apr 2023 to Apr 2024